| PTEN-deficient cancers depend on PIK3CB S Wee, D Wiederschain, SM Maira, A Loo, C Miller, R DeBeaumont, ... Proceedings of the National Academy of Sciences 105 (35), 13057-13062, 2008 | 654 | 2008 |
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers S Wee, Z Jagani, KX Xiang, A Loo, M Dorsch, YM Yao, WR Sellers, ... Cancer research 69 (10), 4286-4293, 2009 | 495 | 2009 |
| Single-vector inducible lentiviral RNAi system for oncology target validation D Wiederschain, W Susan, L Chen, A Loo, G Yang, A Huang, Y Chen, ... Cell cycle 8 (3), 498-504, 2009 | 484 | 2009 |
| Why is cancer drug discovery so difficult? A Kamb, S Wee, C Lengauer Nature reviews Drug discovery 6 (2), 115-120, 2007 | 447 | 2007 |
| BTB/POZ domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases R Geyer, S Wee, S Anderson, J Yates, DA Wolf Molecular cell 12 (3), 783-790, 2003 | 394 | 2003 |
| Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells SM Brachmann, I Hofmann, C Schnell, C Fritsch, S Wee, H Lane, S Wang, ... Proceedings of the National Academy of Sciences 106 (52), 22299-22304, 2009 | 331 | 2009 |
| Fission yeast COP9/signalosome suppresses cullin activity through recruitment of the deubiquitylating enzyme Ubp12p C Zhou, S Wee, E Rhee, M Naumann, W Dubiel, DA Wolf Molecular cell 11 (4), 927-938, 2003 | 232 | 2003 |
| The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases? DA Wolf, C Zhou, S Wee Nature cell biology 5 (12), 1029-1033, 2003 | 228 | 2003 |
| CSN facilitates Cullin–RING ubiquitin ligase function by counteracting autocatalytic adapter instability S Wee, RK Geyer, T Toda, DA Wolf Nature cell biology 7 (4), 387-391, 2005 | 215 | 2005 |
| PCI proteins eIF3e and eIF3m define distinct translation initiation factor 3 complexes C Zhou, F Arslan, S Wee, S Krishnan, AR Ivanov, A Oliva, J Leatherwood, ... BMC biology 3, 1-16, 2005 | 157 | 2005 |
| F-box-directed CRL complex assembly and regulation by the CSN and CAND1 MW Schmidt, PR McQuary, S Wee, K Hofmann, DA Wolf Molecular cell 35 (5), 586-597, 2009 | 147 | 2009 |
| Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression R Lenhart, S Kirov, H Desilva, J Cao, M Lei, K Johnston, R Peterson, ... Molecular cancer therapeutics 14 (10), 2167-2174, 2015 | 103 | 2015 |
| Conservation of the COP9/signalosome in budding yeast S Wee, B Hetfeld, W Dubiel, DA Wolf BMC genetics 3, 1-8, 2002 | 102 | 2002 |
| Targeting epigenetic regulators for cancer therapy S Wee, D Dhanak, H Li, SA Armstrong, RA Copeland, R Sims, SB Baylin, ... Annals of the New York Academy of Sciences 1309 (1), 30-36, 2014 | 91 | 2014 |
| Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice A Hashimoto, C Gao, J Mastio, A Kossenkov, SI Abrams, AV Purandare, ... Cancer research 78 (19), 5644-5655, 2018 | 43 | 2018 |
| Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development S Wee, C Lengauer, D Wiederschain Current opinion in oncology 20 (1), 77-82, 2008 | 36 | 2008 |
| Discovery and preclinical pharmacology of an oral bromodomain and extra-terminal (BET) inhibitor using scaffold-hopping and structure-guided drug design AV Gavai, D Norris, G Delucca, D Tortolani, JS Tokarski, D Dodd, ... Journal of medicinal chemistry 64 (19), 14247-14265, 2021 | 25 | 2021 |
| Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase DP O’Malley, V Ahuja, B Fink, C Cao, C Wang, J Swanson, S Wee, ... ACS Medicinal Chemistry Letters 10 (10), 1486-1491, 2019 | 20 | 2019 |
| Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer J Hilton, MC Cristea, M Voskoboynik, S Postel-Vinay, W Edenfield, ... Annals of Oncology 29, viii134, 2018 | 18 | 2018 |
| Discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancer AV Gavai, D Norris, D Tortolani, D O'Malley, Y Zhao, C Quesnelle, P Gill, ... Cancer Research 78 (13_Supplement), 5789-5789, 2018 | 13 | 2018 |
